PMID- 20132056
OWN - NLM
STAT- MEDLINE
DCOM- 20100429
LR  - 20211020
IS  - 1744-7682 (Electronic)
IS  - 1471-2598 (Print)
IS  - 1471-2598 (Linking)
VI  - 10
IP  - 3
DP  - 2010 Mar
TI  - Challenges of T cell therapies for virus-associated diseases after hematopoietic 
      stem cell transplantation.
PG  - 337-51
LID - 10.1517/14712590903456003 [doi]
AB  - IMPORTANCE OF THE FIELD: Hematopoietic stem cell transplantation (HSCT) is the 
      treatment of choice for many hematological malignancies and genetic disorders. 
      The majority of patients do not have a human leukocyte antigen (HLA) identical 
      sibling donor, and alternative stem cell sources include HLA-matched or 
      mismatched unrelated donors and haploidentical related donors. However, 
      alternative donor HSCT are associated with three major complications i) graft 
      rejection; ii) graft-versus-host disease (GvHD); and iii) delayed immune 
      reconstitution leading to viral infections and relapse. AREAS COVERED IN THIS 
      REVIEW: Graft rejection and the risk of GvHD can be significantly reduced by 
      using intensive conditioning regimens, including in vivo T cell depletion as well 
      as ex vivo T cell depletion of the graft. However, the benefits of removing 
      alloreactive T cells from the graft are offset by the concomitant removal of T 
      cells with anti-viral or anti-tumor activity as well as the profound delay in 
      endogenous T cell recovery post-transplant. Thus, opportunistic infections, many 
      of which are not amenable to conventional small-molecule therapeutics, are 
      frequent in these patients and are associated with significant morbidity and high 
      mortality rates. This review discusses current cell therapies to prevent or treat 
      viral infections/reactivations post-transplant. WHAT THE READER WILL GAIN: The 
      reader will gain an understanding of the current state of cell therapy to prevent 
      and treat viral infections post-HSCT, and will be introduced to preclinical 
      studies designed to develop and validate new manufacturing procedures intended to 
      improve therapeutic efficacy and reduce associated toxicities. TAKE HOME MESSAGE: 
      Reconstitution of HSCT recipients with antigen-specific T cells, produced either 
      by allodepletion or in vitro reactivation, can offer an effective strategy to 
      provide both immediate and long-term protection without harmful alloreactivity.
FAU - Leen, Ann M
AU  - Leen AM
AD  - The Methodist Hospital, Texas Children's Hospital, Center for Cell and Gene 
      Therapy, Baylor College of Medicine, 1102 Bates Street, Houston, TX 77030, USA. 
      amleen@txccc.org
FAU - Tripic, Tamara
AU  - Tripic T
FAU - Rooney, Cliona M
AU  - Rooney CM
LA  - eng
GR  - P01 CA094237-06/CA/NCI NIH HHS/United States
GR  - 1 U54 HL081007/HL/NHLBI NIH HHS/United States
GR  - U54 HL081007/HL/NHLBI NIH HHS/United States
GR  - P01 CA094237/CA/NCI NIH HHS/United States
GR  - U54 HL081007-05/HL/NHLBI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PT  - Review
PL  - England
TA  - Expert Opin Biol Ther
JT  - Expert opinion on biological therapy
JID - 101125414
SB  - IM
MH  - Adoptive Transfer
MH  - Blood Donors
MH  - *Hematopoietic Stem Cell Transplantation
MH  - Humans
MH  - Lymphocyte Depletion
MH  - T-Lymphocytes, Cytotoxic/*cytology
MH  - Virus Diseases/*therapy
PMC - PMC2818535
MID - NIHMS160432
EDAT- 2010/02/06 06:00
MHDA- 2010/04/30 06:00
PMCR- 2011/03/01
CRDT- 2010/02/06 06:00
PHST- 2010/02/06 06:00 [entrez]
PHST- 2010/02/06 06:00 [pubmed]
PHST- 2010/04/30 06:00 [medline]
PHST- 2011/03/01 00:00 [pmc-release]
AID - 10.1517/14712590903456003 [doi]
PST - ppublish
SO  - Expert Opin Biol Ther. 2010 Mar;10(3):337-51. doi: 10.1517/14712590903456003.